Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ijpharm.2007.12.038
DC FieldValue
dc.titleImpact of cross-linker on alginate matrix integrity and drug release
dc.contributor.authorChing, A.L.
dc.contributor.authorLiew, C.V.
dc.contributor.authorHeng, P.W.S.
dc.contributor.authorChan, L.W.
dc.date.accessioned2014-10-29T01:53:56Z
dc.date.available2014-10-29T01:53:56Z
dc.date.issued2008-05-01
dc.identifier.citationChing, A.L., Liew, C.V., Heng, P.W.S., Chan, L.W. (2008-05-01). Impact of cross-linker on alginate matrix integrity and drug release. International Journal of Pharmaceutics 355 (1-2) : 259-268. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijpharm.2007.12.038
dc.identifier.issn03785173
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/106024
dc.description.abstractSodium alginate, a biopolymer, was employed in the formulation of matrix tablets. They cracked or laminated at acidic pH, compromising their dissolution performance. Improved mechanical strength and reduced barrier permeability of calcium alginate gel provided the rationale for cross-linking the alginate matrix to sustain drug release. Studies had suggested that the incorporation of soluble calcium salts in alginate matrix tablets could sustain drug release at near-neutral pH due to in situ cross-linking. However, results from the present study showed otherwise when gastrointestinal pH conditions were simulated. Significant reduction in drug release rate was only observed when an external calcium source was utilized at low concentration. High calcium ion concentrations caused matrix disintegration. In contrast, matrices pre-coated by calcium alginate could sustain drug release at pH 1.2 followed by pH 6.8 for over 12 h. The presence of cross-linked barrier impeded matrix lamination and preserved matrix structure, contributing to at least three-fold reduction in drug release at pH 1.2. Zero order release as well as delayed burst release could be achieved by employing appropriate grade of alginate and cross-linking conditions. © 2008 Elsevier B.V. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ijpharm.2007.12.038
dc.sourceScopus
dc.subjectBarrier preservation
dc.subjectCross-linking
dc.subjectDisintegration
dc.subjectLamination
dc.subjectModified release
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.description.doi10.1016/j.ijpharm.2007.12.038
dc.description.sourcetitleInternational Journal of Pharmaceutics
dc.description.volume355
dc.description.issue1-2
dc.description.page259-268
dc.description.codenIJPHD
dc.identifier.isiut000255696200030
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

23
checked on Sep 16, 2020

WEB OF SCIENCETM
Citations

18
checked on Sep 16, 2020

Page view(s)

82
checked on Sep 12, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.